Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;101(1):e26-e42.
doi: 10.1111/aos.15201. Epub 2022 Jul 5.

The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden

Richard P Gale  1 , Robert P Finger  2 , Bora Eldem  3 , Tariq Aslam  4   5 , Jane Barratt  6 , Vincent Daien  7 , Laurent Kodjikian  8   9 , Anat Loewenstein  10 , Mali Okada  11 , Tien Yin Wong  12   13 , Michelle Sylvanowicz  14 , Francisco J Rodríguez  15
Affiliations

The management of neovascular age-related macular degeneration: A systematic literature review of patient-reported outcomes, patient mental health and caregiver burden

Richard P Gale et al. Acta Ophthalmol. 2023 Feb.

Abstract

Purpose: The aim of this systematic literature review was to describe patient-reported outcomes, mental health and caregiver burden in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents in routine clinical practice.

Methods: Electronic searches were conducted in Embase and MEDLINE according to pre-defined criteria.

Results: Of 856 records identified, 63 met inclusion criteria. Depression or depressive symptoms were reported in up to 42% of patients with nAMD. Of 25/63 (40%) studies evaluating quality of life (QoL) and using various tools, eight studies reported composite National Eye Institute Visual Functioning Questionnaire scores following anti-VEGF treatment. Of these, seven reported a statistically significant improvement at the earliest time point measured (Month 3-12) and approximately 50% reported sustained QoL benefits at 12 months. In studies comparing the attributed or different regimens, the most important factor from the patient's perspective was the likelihood that a particular regimen would maintain vision. There was a preference towards treat and extend, which was associated with a perceived reduction in patient and caregiver burden, compared to fixed dosing.

Conclusions: A coordinated holistic approach to patient care is key to optimizing patient well-being as well as visual outcomes. Further research regarding the patient-reported impact of nAMD management outside the trial setting (particularly international longitudinal studies) is warranted. Standardization of QoL studies would assist in establishing whether sustained QoL improvement, rather than prevention of QoL decline, should be a realistic expectation of treatment of nAMD in the longer term.

Keywords: intravitreal injections; mental health; neovascular age-related macular degeneration; patient care; quality of life.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
PRISMA flow diagram
See this image and copyright information in PMC

References

    1. Arruabarrena, C. , Toro, M.D. , Onen, M. , Malyugin, B.E. , Rejdak, R. , Tognetto, D. et al. (2021) Impact on visual acuity in neovascular age related macular degeneration (nAMD) in Europe due to COVID‐19 pandemic lockdown. Journal of Clinical Medicine, 10, 3281. - PMC - PubMed
    1. Bertelmann, T. , Feltgen, N. , Scheffler, M. , Hufenbach, U. , Wiedon, A. , Wilhelm, H. et al. (2016) Vision‐related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study. Health and Quality of Life Outcomes, 14, 132. - PMC - PubMed
    1. Bhagat, D. , Kirby, B. , Bhatt, H. , Jager, R. , George, M. & Sheth, V. (2020) Patient preferences associated with anti‐vascular endothelial growth factor therapies for neovascular age‐related macular degeneration and diabetic macular edema. Clinical Ophthalmology, 14, 2975–2982. - PMC - PubMed
    1. Bian, W. , Wan, J. , Tan, M. , Su, J. , Yuan, Y. , Wang, Z. et al. (2020) Predictors of health‐related quality of life in Chinese patients receiving treatment for neovascular age‐related macular degeneration: a prospective longitudinal study. BMC Ophthalmology, 20, 291. - PMC - PubMed
    1. Bobykin, E. , Korotkikh, S. & Nerus, I. (2018) Evaluation of quality of life and treatment satisfaction of patients receiving anti‐VEGF therapy. Ophthalmic Research, 60, 4.

Publication types

Substances

Grants and funding